Regulus Therapeutics
RGLS
#7200
Rank
โ‚ฌ0.51 B
Marketcap
7,44ย โ‚ฌ
Share price
0.00%
Change (1 day)
464.66%
Change (1 year)

Earnings for Regulus Therapeutics (RGLS)

Earnings in 2025 (TTM): -โ‚ฌ44.02 Million

According to Regulus Therapeutics's latest financial reports the company's current earnings are N/A. In 2024 the company made an earning of -โ‚ฌ42.11 Million a decrease over its 2023 earnings that were of -โ‚ฌ26.83 Million. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Regulus Therapeutics from 2012 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) -โ‚ฌ44.02 Million4.53%
2024 -โ‚ฌ42.11 Million56.97%
2023 -โ‚ฌ26.83 Million6.51%
2022 -โ‚ฌ25.19 Million2.53%
2021 -โ‚ฌ24.57 Million93.59%
2020 -โ‚ฌ12.69 Million-15.41%
2019 -โ‚ฌ15 Million-64.46%
2018 -โ‚ฌ42.21 Million-33.26%
2017 -โ‚ฌ63.24 Million-13.98%
2016 -โ‚ฌ73.52 Million44.77%
2015 -โ‚ฌ50.78 Million-1.63%
2014 -โ‚ฌ51.63 Million203.6%
2013 -โ‚ฌ17.01 Million8.65%
2012 -โ‚ฌ15.65 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Sanofi
SNY
โ‚ฌ7.09 B-16,520.40%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚ฌ0.40 B-1,038.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ10.32 B-23,992.56%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ13.75 B-31,913.87%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚ฌ6.52 B-15,184.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
-โ‚ฌ0.11 Billion 132.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Dicerna Pharmaceuticals
DRNA
-โ‚ฌ0.11 Billion 148.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚ฌ1.11 B-2,675.32%๐Ÿ‡บ๐Ÿ‡ธ USA